March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
April 2017 in “The Journal of Urology” Finasteride before TURP reduces blood loss and improves early postoperative quality of life.
39 citations,
April 2007 in “Therapeutic Drug Monitoring” Finasteride affects urinary steroid profiles and can potentially hide steroid abuse in sports drug testing.
34 citations,
January 1998 in “European Urology” Finasteride works best in 6 months and lasts 6 years.
March 2023 in “Enciclopédia Biosfera” Finasteride effectively treats BPH but requires continuous use to maintain benefits.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
October 2010 in “Journal of Men's Health” The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
March 2016 in “European Urology Supplements” Methylation in specific gene region causes finasteride resistance in some BPH patients.
13 citations,
May 2018 in “Urologic Oncology: Seminars and Original Investigations” Finasteride does not prevent bladder cancer.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
76 citations,
September 1992 in “Endocrinology” The human type II 5α-reductase gene has a specific structure important for understanding certain medical conditions.
17 citations,
February 2001 in “Urologia Internationalis” Stopping alpha-blocker medication after 6-9 months is safe and effective for most patients with bladder outlet obstruction.
August 2014 in “Acta Crystallographica” Different forms of finasteride dissolve and remain stable differently, affecting capsule quality.
October 1999 in “The Journal of Urology” New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.
3 citations,
October 1995 in “Southern Medical Journal” Finasteride may cause breast enlargement, low testosterone a risk factor.
12 citations,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
January 2018 in “International Journal of Medical Research and Health Sciences” Finasteride reduces blood loss and the need for blood transfusions during and after TURP surgery.
11 citations,
January 2018 in “Asian Journal of Andrology” Dutasteride caused more penile tissue changes than finasteride, possibly increasing erectile dysfunction risk.
82 citations,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
20 citations,
August 2018 in “The World Journal of Men's Health” Finasteride may increase erectile dysfunction risk in patients with benign prostatic hyperplasia.
1707 citations,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
June 2008 in “Drugs & therapy perspectives” Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
1 citations,
March 2023 in “Scientific Reports” Finasteride may increase the risk of suicide or severe self-harm in men with mood disorders but not in the general population.
3 citations,
January 2018 in “Reproduction, Fertility and Development” Birth control pills increase certain receptor activities in female gerbil prostate glands and can lead to prostate changes.
Men with depression and marijuana usage are more likely to be treated for lower urinary tract symptoms/benign prostatic hyperplasia.
53 citations,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.